Pipeline

EU501 (HER2 x 4-1BB)
Indication HER2 positive solid cancer Target /Drug class Anti-human 4-1BB/HER2 mBsAb Development Stage Non-clinical
Summary
  • Tumor cell-specific killing effect – low side effects
  • Better efficacy for tumor clearance than monospecific antibody
In vitro/in vivo Efficacy
Mode of Action